<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A4682</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.fronterpagebillhead
	{mso-style-name:fronterpagebillhead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FPHangingAnAct, li.FPHangingAnAct, div.FPHangingAnAct
	{mso-style-name:FPHangingAnAct;
	mso-style-link:"FPHangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.4in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.FPHangingAnActChar
	{mso-style-name:"FPHangingAnAct Char";
	mso-style-link:FPHangingAnAct;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	letter-spacing:.2pt;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	letter-spacing:.2pt;
	font-weight:bold;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.0in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.3in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 4682 </p>

<p class=bpuWpGraphic><b><span style='font-size:32.0pt;line-height:120%;
font-family:"Arial",sans-serif;letter-spacing:0pt'>STATE OF NEW JERSEY</span></b></p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>INTRODUCED SEPTEMBER 12, 2024</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:11.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  ANTHONY S. VERRELLI</p>

<p class=bpuSponsor>District 15 (Hunterdon and Mercer)</p>

<p class=bpuSponsor>Assemblywoman  MARGIE DONLON, M.D.</p>

<p class=bpuSponsor>District 11 (Monmouth)</p>

<p class=bpuSponsor>Assemblywoman  CAROL A. MURPHY</p>

<p class=bpuSponsor>District 7 (Burlington)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Assemblywoman Drulis, Assemblyman Freiman and Assemblywoman
Park</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Prohibits health insurance carriers from denying
coverage of nonopioid prescription drugs in favor of opioid prescription drugs.</p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     As introduced.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif;
letter-spacing:.2pt'><br clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> </span>concerning nonopioid medication and
supplementing various parts of the statutory law.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    a. Notwithstanding any
law, rule, or regulation to the contrary, when a licensed health care provider
prescribes a nonopioid medication to a covered person for the treatment of
acute pain, it shall be unlawful for a carrier to deny coverage of a nonopioid
prescription drug: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   in favor of an opioid
prescription drug; or</p>

<p class=MsoNormal style='line-height:150%'>     (2)   to require a covered
person to try an opioid prescription drug prior to approving the use of a
nonopioid prescription drug.</p>

<p class=MsoNormal style='line-height:150%'>     b.    If a carrier establishes
and maintains a drug formulary, the carrier shall ensure that a nonopioid drug
approved by the United States Food and Drug Administration for the treatment or
management of pain will not be disadvantaged or discouraged, with respect to
coverage or cost-sharing, relative to any opioid or narcotic drug for the
treatment or management of pain on the formulary of the carrier, where
impermissible disadvantaging or discouragement includes, without limitation:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   imposing more
restrictive coverage criteria on any nonopioid drug than the least restrictive
criteria imposed on an opioid or narcotic drug; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   establishing more
restrictive or more extensive utilization controls, including, but not limited
to, more restrictive or more extensive prior authorization or step therapy
requirements, for nonopioid drugs than the least restrictive or extensive
utilization controls applicable to an opioid or narcotic drug; or</p>

<p class=MsoNormal style='line-height:150%'>     (3)   if the carrier maintains
a formulary grouped into tiers for the purposes of determining cost-sharing,
placing any nonopioid drug on a tier that requires a cost-sharing
responsibility that exceeds the lowest cost-sharing responsibility required for
an opioid or narcotic drug on the formulary.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Subsection b. of this
section shall not preclude: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   opioid drugs from being
preferred over other opioid drugs; or</p>

<p class=MsoNormal style='line-height:150%'>     (2)   nonopioid drugs from
being preferred over other nonopioid drugs.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.     a.  Notwithstanding any
law, rule, or regulation to the contrary, the State Health Benefits Commission
shall ensure that in every contract providing hospital or medical expense
benefits that is purchased by the commission on or after the effective date of
this act, a nonopioid medication prescribed to a covered person for the
treatment of acute pain shall not be denied coverage: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   in favor of an opioid
prescription drug; or</p>

<p class=MsoNormal style='line-height:150%'>     (2)   so that a covered person
be required to try an opioid prescription drug prior to approving the use of a
nonopioid prescription drug.</p>

<p class=MsoNormal style='line-height:150%'>     b.    For contracts that use
and maintain a drug formulary, it shall be required that a nonopioid drug
approved by the United States Food and Drug Administration for the treatment or
management of pain will not be disadvantaged or discouraged, with respect to
coverage or cost-sharing, relative to any opioid or narcotic drug for the
treatment or management of pain on the formulary.  Impermissible disadvantaging
or discouragement includes, without limitation:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   imposing more
restrictive coverage criteria on any nonopioid drug than the least restrictive
criteria imposed on an opioid or narcotic drug; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   establishing more
restrictive or more extensive utilization controls, including, but not limited
to, more restrictive or more extensive prior authorization or step therapy
requirements, for nonopioid drugs than the least restrictive or extensive
utilization controls applicable to an opioid or narcotic drug; or</p>

<p class=MsoNormal style='line-height:150%'>     (3)   if the contract uses and
maintains a formulary grouped into tiers for the purposes of determining
cost-sharing, placing any nonopioid drug on a tier that requires a cost-sharing
responsibility that exceeds the lowest cost-sharing responsibility required for
an opioid or narcotic drug on the formulary.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Subsection b. of this
section shall not preclude: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   opioid drugs from being
preferred over other opioid drugs; or</p>

<p class=MsoNormal style='line-height:150%'>     (2)   nonopioid drugs from
being preferred over other nonopioid drugs.</p>

<p class=MsoNormal style='line-height:150%'>   </p>

<p class=MsoNormal style='line-height:150%'>     3.    a.  Notwithstanding any
law, rule, or regulation to the contrary, the School Employees Health Benefits
Commission shall ensure that in every contract providing hospital or medical
expense benefits, which is purchased by the commission on or after the
effective date of this act, a nonopioid medication prescribed to a covered
person for the treatment of acute pain shall not be denied coverage: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   in favor of an opioid
prescription drug; or</p>

<p class=MsoNormal style='line-height:150%'>     (2)   so that a covered person
be required to try an opioid prescription drug prior to approving the use of a
nonopioid prescription drug.</p>

<p class=MsoNormal style='line-height:150%'>     b.    For contracts that use
and maintain a drug formulary, it shall be required that a nonopioid drug
approved by the United States Food and Drug Administration for the treatment or
management of pain will not be disadvantaged or discouraged, with respect to
coverage or cost-sharing, relative to any opioid or narcotic drug for the
treatment or management of pain on the formulary, where impermissible
disadvantaging or discouragement includes, without limitation:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   imposing more
restrictive coverage criteria on any nonopioid drug than the least restrictive
criteria imposed on an opioid or narcotic drug; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   establishing more
restrictive or more extensive utilization controls, including, but not limited
to, more restrictive or more extensive prior authorization or step therapy
requirements, for nonopioid drugs than the least restrictive or extensive
utilization controls applicable to an opioid or narcotic drug; or</p>

<p class=MsoNormal style='line-height:150%'>     (3)   if the contract uses and
maintains a formulary grouped into tiers for the purposes of determining
cost-sharing, placing any nonopioid drug on a tier that requires a cost-sharing
responsibility that exceeds the lowest cost-sharing responsibility required for
an opioid or narcotic drug on the formulary.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Subsection b. of this
section shall not preclude: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   opioid drugs from being
preferred over other opioid drugs; or</p>

<p class=MsoNormal style='line-height:150%'>     (2)   nonopioid drugs from
being preferred over other nonopioid drugs.</p>

<p class=MsoNormal style='line-height:150%'>     </p>

<p class=MsoNormal style='line-height:150%'>     4.    a.  Notwithstanding any
State law, rule, or regulation to the contrary, whenever a licensed health care
provider prescribes a nonopioid medication for the treatment of acute pain to
persons served under the Medicaid program, established pursuant to P.L.1968,
c.413 (C.30:4D-1 et seq.), the Department of Human Services shall not deny
coverage of the nonopioid prescription drug: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   in favor of an opioid
prescription drug; or</p>

<p class=MsoNormal style='line-height:150%'>     (2)   so that a covered person
be required to try an opioid prescription drug prior to approving use of a
nonopioid prescription drug.</p>

<p class=MsoNormal style='line-height:150%'>     b.    In establishing and
maintaining a preferred drug list, the Department of Human Services shall
ensure that nonopioid drugs on the list, and approved by the United States Food
and Drug Administration, for the treatment or management of pain shall not be
disadvantaged or discouraged with respect to coverage relative to any opioid or
narcotic drug for the treatment or management of pain. </p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     5.    This act shall take
effect on January 1, 2026 and shall apply to policies, plans, and contracts
that are delivered, issued, executed, or renewed on or after that date.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill makes it unlawful
when a licensed health care provider prescribes a nonopioid medication to a
person covered by a health insurance carrier for the treatment of acute pain
and the carrier denies coverage of a nonopioid prescription drug:  (1) in favor
of an opioid prescription drug; or (2) to require a covered person to try an
opioid prescription drug prior to approving the use of a nonopioid prescription
drug.  Carrier is defined in the bill to mean an insurance company, health
service corporation, hospital service corporation, medical service corporation,
or health maintenance organization authorized to issue health benefits plans in
this State.  </p>

<p class=MsoNormal style='line-height:150%'>     Under the bill, a carrier that
establishes and maintains a drug formulary is to ensure that a nonopioid drug
approved by the United States Food and Drug Administration for the treatment or
management of pain will not be disadvantaged or discouraged, with respect to
coverage or cost-sharing, relative to any opioid or narcotic drug for the
treatment or management of pain on the formulary of the carrier under various
circumstances.  It is not prohibited in the bill for an opioid drug to be preferred
over another opioid drug or for a nonopioid drug to be preferred over another
nonopioid drug.</p>

<p class=MsoNormal style='line-height:150%'>     The provisions of the bill
prohibiting denial of a nonopioid prescription drug are also incorporated into
the laws governing the required coverage for contracts negotiated by the State
Health Benefits Commission and the School Employees Health Benefits
Commission, and in the law overseeing Medicaid. </p>

</div>

</body>

</html>
